The National Agency for Food and Drug Administration and Control (NAFDAC) has said two batches of Cardura XL (doxazosin mesylate) extended-release tablets were recalled from the market because they were substandard.

Cardura XL extended-release tablets are alpha-adrenergic blockers used to either treat hypertension or improve urination in men with benign prostatic hyperplasia (enlarged prostate).

According to a post on NAFDAC’s X page on Monday, the drug lots are being recalled because they failed to meet impurity and degradation specifications.

READ ALSO: ALERT: Fake Herceptin, a Breast Cancer Drug, in Nigerian Markets Since 2023

Public Alert No. 038/2024.Alert on recall of Cardura XL (Doxazosin) Extended-Release Tablets#NafdacALERTShttps://t.co/LhtHXvrM2W— NAFDAC NIGERIA (@NafdacAgency) September 23, 2024

“NAFDAC is notifying the public of the recall of two (2) lots of a hypertension drug, Cardura XL (Doxazosin) extended-release tablets (8mg and 4mg), manufactured by American global pharmaceutical and healthcare company, Viatris Inc. with lot numbers 81470418163765 and 81470408163764,” wrote the agency.

“Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office.”

READ ALSO: Alert: NAFDAC Says Caro White Lotion Puts Users at Risk of Endocrine Disruption

In an earlier statement issued on the tablets, NAFDAC noted that the consequences of poor-quality drugs include ineffective treatment, increased risk of adverse events, allergic reactions, anxiety, and general harm to patients and even death.

FIJ has reported more incidents of substandard, fake and poisonous drugs hitting the Nigerian market here, here and here.
The post ALERT: Substandard Cardura XL for Hypertension Enters Nigerian Markets appeared first on Foundation For Investigative Journalism.